Shanghai / Palo Alto / Wetzlar / Nanjing / San Diego / Chicago / St. Louis / Santa Cruz / /
Company
CaOV3 / IgG / USA AB / SPSS / Macmillan Publishers Limited / /
Country
Germany / United States / China / / /
Event
M&A / /
Facility
Affiliated BenQ Hospital of Nanjing Medical University / Jiangsu Province Hospital of TCM / Nanjing Medical University / China Pharmaceutical University / HDAC6/PP1 complex / PP1/HDACs complex / PP1 complex / First Affiliated Hospital of Nanjing Medical University / /
IndustryTerm
concurrent applications / treatment of T-cell lymphoma / /
MedicalCondition
vivo human tumor / ovarian cancer / moderately inhibited tumor / pancreatic and ovarian cancer / Moderate cancer / significantly smaller tumor / human tumor / HDACIs-induced cancer / pancreatic and ovarian carcinoma / SKOV3 ovarian cancer / CaOV3 ovarian cancer / melanoma / reduced tumor / pancreatic cancer / tumor / ng/ml Cancer / TSA-induced cancer / cancer / tumors / Disease / cancer cells / hepatoma cells HepG2 / HDACIsinduced cancer / SAHA-induced cancer / human hepatoma cell / different cancer / CaOV3 tumor / /
MedicalTreatment
chemotherapy / /
OperatingSystem
L3 / /
Organization
Akt association / PP2A26 / Department of Dermatology / PR China and 6Jiangsu Province Key Lab of Neurodegeneration / Affiliated BenQ Hospital / PP1 association / Nanjing Medical University / Nanjing / Department of Pharmacology / TSA administration / Jiangsu Province Key Lab of Neurodegeneration / Department of Physiology / Jiangsu Province Hospital of TCM / China Pharmaceutical University / Nanjing / FDA / First Affiliated Hospital / /
Citation: Cell Death and Disease[removed], e117; doi:[removed]cddis[removed] & 2011 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis C6-ceramide synergistically potentiates the anti-tumor